PAR-100.2

PAR-100.2 is an inhaled small molecule inhibitor of the epithelial sodium channel (ENaC), developed by Parion Sciences for the treatment of cystic fibrosis. The drug is designed to block the ENaC protein on the apical surface of airway epithelial cells, which is typically overactive in cystic fibrosis patients. By inhibiting this channel, PAR-100.2 prevents the excessive reabsorption of sodium and the subsequent osmotic movement of water out of the airway surface liquid (ASL). This preservation of ASL volume helps maintain mucus hydration and facilitates mucociliary clearance, a critical defense mechanism that is impaired in cystic fibrosis. Clinical development reached Phase 2, but the program was later superseded by more potent, longer-acting ENaC inhibitors in the developer's pipeline.

Other names

P-1001P1001P 1001